MeVis Medical Solutions AG (FRA:M3V) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


FRA:M3V MeVis Medical Solutions AG FRA:M3V
66 GF Score
Price €23.20
GF Value €22.52
! 4 Warning Signs
View Full Analysis

What is MeVis Medical Solutions AG Research & Development?

MeVis Medical Solutions AG FRA:M3V 66 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MeVis Medical Solutions AG's Research & Development for the six months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

MeVis Medical Solutions AG  (FRA:M3V) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MeVis Medical Solutions AG Research & Development Related Terms

MeVis Medical Solutions AG Research & Development Historical Data

* Premium members only.

The historical data trend for MeVis Medical Solutions AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeVis Medical Solutions AG Research & Development Chart

MeVis Medical Solutions AG Annual Data
Trend Dec15 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MeVis Medical Solutions AG Semi-Annual Data
Jun16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:M3V
66GF Score
MeVis Medical Solutions AG FRA:M3V
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeVis Medical Solutions AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
MeVis Medical Solutions AG (FRA:M3V) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MeVis Medical Solutions AG and its competitors.
Is MeVis Medical Solutions AG's Research & Development too high?
MeVis Medical Solutions AG's current Research & Development is €0.00 Mil. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's Research & Development compare to VEEV and BTSG?
MeVis Medical Solutions AG's Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MeVis Medical Solutions AG and its competitors. MeVis Medical Solutions AG's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €22.52, compared to a current price of €23.20 — trading 3% above its estimated fair value. The current Research & Development is €0.00 Mil. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?

Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued. The current stock price of €23.20 is trading 3% above its estimated GF Value™ of €22.52.

Key valuation signals for FRA:M3V:

  • Research & Development: €0.00 Mil
  • GF Value™: €22.52 vs. price of €23.20 (3% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeVis Medical Solutions AG Business Description

Other Exchanges 0HI7:UKM3V:Germany
Address Caroline-Herschel-Strasse 1, Bremen, DEU, 28359
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score

Get the complete analysis for FRA:M3V

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.20
Price
€22.52
GF Value